Torthaí cuardaigh - Scott, Rob

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism de réir Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab de réir Desai, Nihar R., Giugliano, Robert P., Wasserman, Scott M., Gibbs, John P., Liu, Thomas, Scott, Rob, Sabatine, Marc S.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hyperc... de réir Cho, Leslie, Rocco, Michael, Colquhoun, David, Sullivan, David, Rosenson, Robert S., Dent, Ricardo, Xue, Allen, Scott, Rob, Wasserman, Scott M, Stroes, Erik

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Par... de réir Kohli, Payal, Ganz, Peter, Ma, Yifei, Scherzer, Rebecca, Hur, Sophia, Weigel, Bernard, Grunfeld, Carl, Deeks, Steven, Wasserman, Scott, Scott, Rob, Hsue, Priscilla Y.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hy... de réir Robinson, Jennifer G., Rogers, William J., Nedergaard, Bettina S., Fialkow, Jonathan, Neutel, Joel M., Ramstad, David, Somaratne, Ransi, Legg, Jason C., Nelson, Patric, Scott, Rob, Wasserman, Scott M., Weiss, Robert

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role de réir Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subj... de réir Nissen, Steven E., Dent‐Acosta, Ricardo E., Rosenson, Robert S., Stroes, Erik, Sattar, Naveed, Preiss, David, Mancini, G.B. John, Ballantyne, Christie M., Catapano, Alberico, Gouni‐Berthold, Ioanna, Stein, Evan A., Xue, Allen, Wasserman, Scott M., Scott, Rob, Thompson, Paul D.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán